Cava Healthcare Announces Notification of Patent Allowance from the United States Patent and Trademark Office for a New Class of Alzheimer's Disease Drugs
Patent Provides Cava Healthcare Exclusivity
Vancouver, British Columbia – TheNewswire - November 20, 2023 – Cava Healthcare Inc. (Cava), a biopharmaceutical company focused on commercialization and development of therapeutics to improve the lives of patients with Alzheimer’s disease, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 17/025,241. This application includes claims intended to protect a drug-based new approach for treating Alzheimer’s disease. A Notice of Allowance is issued after the USPTO has determined that an invention is novel. After issuance, Cava plans to raise funds immediately to commence clinical trials on its lead compounds for treating Alzheimer’s disease.
"This allowance is significant in that it provides Cava with a potentially dominant intellectual property position on a new approach for the treatment of Alzheimer’s disease. We have completed several successful proof-of concept studies in preclinical models of Alzheimer’s disease where the results clearly demonstrate that this innovative approach reduces amyloid plaque burden in the brain resulting in a concurrent recovery of cognitive memory. These studies underscore the promising nature of this new approach,” stated Dr. Wilfred Jefferies, CSO of Cava.
The issuance of this Notice of Allowance marks a significant milestone in Cava's pursuit of safeguarding the commercial viability of drugs aimed at neurological diseases, including Alzheimer’s disease. This protection is being achieved through a strategic combination of patent coverage, regulatory exclusivity, and trade secrets, further bolstered by leveraging additional barriers to entry. Numerous patent applications have either been issued or allowed by the USPTO, and a considerable number of additional applications are currently pending in the United States. Beyond the U.S., Cava is actively pursuing patent applications in various jurisdictions, including a method of use patent application in Europe, for which Cava has recently announced the receipt of an Intention to Grant letter.
The Company additionally announces the resignation of Mr. Theo Warkentin as Director, and we extend our gratitude for his contributions to Cava.
For further information, please contact Adrian Wade at email@example.com.
On Behalf of the Board of Directors
Adrian Wade, Ph.D.
COO and Director
CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE
Cava is a specialty biotechnology company focused on advancing drug development to address unmet medical needs in neurodegeneration, inflammation, and restoration of immune function. The Company has a patent protected portfolio of intellectual property and technology, concentrated on the development of a treatment for Alzheimer’s Disease and various oncology related biomarkers and treatments.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future including, without limitation, matters related to the Company’s current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.